Acerca de
Nuestra Labor
Datos y herramientas
Eventos
Noticias
logo
stock

Sustitutos de los dispositivos de reconstitución BAXJECT II/BAXJECT II Hi-Flow empacados con Advate/Feiba/Rixubis

Takeda decidió voluntariamente sustituir los dispositivos de reconstitución BAXJECT II y BAXJECT II Hi-Flow producidos por el fabricante de dispositivos contratado por Takeda entre octubre de 2021 y enero de 2022. Esta es una medida precautoria debida a la posible presencia de partículas en el puerto luer del dispositivo. El problema está relacionado con el dispositivo y no con la calidad del producto de tratamiento, ni con cualquier otro componente del paquete. Ninguno de los eventos adversos reportados en las bases de datos de seguridad mundial de Takeda se atribuyó a la presencia de partículas en los dispositivos BAXJECT II/BAXJECT II Hi-Flow.

También disponible en: English Français

Takeda identificó a los países que recibieron los lotes afectados y trabaja con autoridades de salud regionales, nacionales y locales a fin de tomar medidas correctivas, las cuales podrán variar según el país. De acuerdo con la Agencia Europea de Medicamentos, Takeda colaborará con las autoridades de salud de los países identificados en Europa a fin de proporcionar sustitutos de los dispositivos de reconstitución BAXJECT II y BAXJECT II Hi-Flow a profesionales de la salud que hayan recibido dispositivos de los lotes afectados.

Los dispositivos de reconstitución BAXJECT II y BAXJECT II Hi-Flow que forman parte de los lotes enumerados deberían desecharse y los dispositivos que los sustituyen deberían usarse según las instrucciones de la documentación de información del producto.

Para obtener más información haga clic aquí. Para leer la declaración de Takeda haga clic aquí. Para leer la declaración del Consorcio Europeo de Hemofilia haga clic aquí. Para leer la declaración por la National Bleeding Disorders Foundation (NBDF) haga clic aquí.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.